162 related articles for article (PubMed ID: 23658483)
1. A tissue-engineered subcutaneous pancreatic cancer model for antitumor drug evaluation.
He Q; Wang X; Zhang X; Han H; Han B; Xu J; Tang K; Fu Z; Yin H
Int J Nanomedicine; 2013; 8():1167-76. PubMed ID: 23658483
[TBL] [Abstract][Full Text] [Related]
2. A bioengineered murine model using CD24⁺CD44⁺ pancreatic cancer stem cells for chemotherapy study.
Qin S; Deng Y; Li J; Zhang Z
Biomed Mater; 2014 Dec; 10(1):015004. PubMed ID: 25532534
[TBL] [Abstract][Full Text] [Related]
3. A bioengineered metastatic pancreatic tumor model for mechanistic investigation of chemotherapeutic drugs.
Wang X; Zhang X; Fu Z; Yin H
J Biotechnol; 2013 Jul; 166(4):166-73. PubMed ID: 23747489
[TBL] [Abstract][Full Text] [Related]
4. Drug-eluting scaffold to deliver chemotherapeutic medication for management of pancreatic cancer after surgery.
Zhan Q; Shen B; Deng X; Chen H; Jin J; Zhang X; Peng C; Li H
Int J Nanomedicine; 2013; 8():2465-72. PubMed ID: 23885173
[TBL] [Abstract][Full Text] [Related]
5. A tissue-engineered gastric cancer model for mechanistic study of anti-tumor drugs.
Gao M; Cai Y; Wu W; Shi Y; Fei Z
Biomed Mater; 2013 Aug; 8(4):045003. PubMed ID: 23715169
[TBL] [Abstract][Full Text] [Related]
6. The Chemotherapeutic Effect of Docetaxel, Cisplatin and Fluorouracil Regimen on Gastric Cancer Stem Cells.
Wang X; Zhang F; Yang J; Huang X; Chao X; Ayidu A; Abudureyimu A
J Nanosci Nanotechnol; 2017 Feb; 17(2):983-99. PubMed ID: 29671949
[TBL] [Abstract][Full Text] [Related]
7. Establishment of a pancreatic cancer stem cell model using the SW1990 human pancreatic cancer cell line in nude mice.
Pan Y; Gao S; Hua YQ; Liu LM
Asian Pac J Cancer Prev; 2015; 16(2):437-42. PubMed ID: 25684468
[TBL] [Abstract][Full Text] [Related]
8. Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma.
Aboukameel A; Muqbil I; Senapedis W; Baloglu E; Landesman Y; Shacham S; Kauffman M; Philip PA; Mohammad RM; Azmi AS
Mol Cancer Ther; 2017 Jan; 16(1):76-87. PubMed ID: 28062705
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of gemcitabine and oxaliplatin is augmented by thymoquinone in pancreatic cancer.
Banerjee S; Kaseb AO; Wang Z; Kong D; Mohammad M; Padhye S; Sarkar FH; Mohammad RM
Cancer Res; 2009 Jul; 69(13):5575-83. PubMed ID: 19549912
[TBL] [Abstract][Full Text] [Related]
10. Side population in the pancreatic cancer cell lines SW1990 and CFPAC-1 is enriched with cancer stem-like cells.
Yao J; Cai HH; Wei JS; An Y; Ji ZL; Lu ZP; Wu JL; Chen P; Jiang KR; Dai CC; Qian ZY; Xu ZK; Miao Y
Oncol Rep; 2010 May; 23(5):1375-82. PubMed ID: 20372854
[TBL] [Abstract][Full Text] [Related]
11. Bitter melon juice intake with gemcitabine intervention circumvents resistance to gemcitabine in pancreatic patient-derived xenograft tumors.
Dhar D; Raina K; Kumar D; Wempe MF; Bagby SM; Pitts TM; Orlicky DJ; Agarwal C; Messersmith WA; Agarwal R
Mol Carcinog; 2020 Oct; 59(10):1227-1240. PubMed ID: 32816368
[TBL] [Abstract][Full Text] [Related]
12. Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer.
Yabuuchi S; Pai SG; Campbell NR; de Wilde RF; De Oliveira E; Korangath P; Streppel MM; Rasheed ZA; Hidalgo M; Maitra A; Rajeshkumar NV
Cancer Lett; 2013 Jul; 335(1):41-51. PubMed ID: 23402814
[TBL] [Abstract][Full Text] [Related]
13. Exosomes derived from cancer stem cells of gemcitabine-resistant pancreatic cancer cells enhance drug resistance by delivering miR-210.
Yang Z; Zhao N; Cui J; Wu H; Xiong J; Peng T
Cell Oncol (Dordr); 2020 Feb; 43(1):123-136. PubMed ID: 31713003
[TBL] [Abstract][Full Text] [Related]
14. Oxaliplatin-incorporated micelles eliminate both cancer stem-like and bulk cell populations in colorectal cancer.
Wang K; Liu L; Zhang T; Zhu YL; Qiu F; Wu XG; Wang XL; Hu FQ; Huang J
Int J Nanomedicine; 2011; 6():3207-18. PubMed ID: 22238509
[TBL] [Abstract][Full Text] [Related]
15. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development.
Jimeno A; Feldmann G; Suárez-Gauthier A; Rasheed Z; Solomon A; Zou GM; Rubio-Viqueira B; García-García E; López-Ríos F; Matsui W; Maitra A; Hidalgo M
Mol Cancer Ther; 2009 Feb; 8(2):310-4. PubMed ID: 19174553
[TBL] [Abstract][Full Text] [Related]
16. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1.
Melisi D; Xia Q; Paradiso G; Ling J; Moccia T; Carbone C; Budillon A; Abbruzzese JL; Chiao PJ
J Natl Cancer Inst; 2011 Aug; 103(15):1190-204. PubMed ID: 21743023
[TBL] [Abstract][Full Text] [Related]
17. Identification and characterization of cancer stem cells in human head and neck squamous cell carcinoma.
Han J; Fujisawa T; Husain SR; Puri RK
BMC Cancer; 2014 Mar; 14():173. PubMed ID: 24612587
[TBL] [Abstract][Full Text] [Related]
18. CD44(+)/CD24(-) breast cancer cells exhibit phenotypic reversion in three-dimensional self-assembling peptide RADA16 nanofiber scaffold.
Mi K; Xing Z
Int J Nanomedicine; 2015; 10():3043-53. PubMed ID: 25945050
[TBL] [Abstract][Full Text] [Related]
19. CD44-positive cells are responsible for gemcitabine resistance in pancreatic cancer cells.
Hong SP; Wen J; Bang S; Park S; Song SY
Int J Cancer; 2009 Nov; 125(10):2323-31. PubMed ID: 19598259
[TBL] [Abstract][Full Text] [Related]
20. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
Chaudhary AK; Mondal G; Kumar V; Kattel K; Mahato RI
Cancer Lett; 2017 Aug; 402():1-8. PubMed ID: 28536008
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
